ClinicalTrials.Veeva

Menu

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 3

Conditions

Type 2 Diabetes Mellitus

Treatments

Drug: exenatide, long acting release
Drug: exenatide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00308139
2993LAR-105 (DURATION - 1)
MB001-010 (Other Identifier)

Details and patient eligibility

About

A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.

Full description

This trial is designed to examine the effect of exenatide once weekly compared to exenatide twice daily on glucose control and safety in subjects for at least 30 weeks. The study is also designed to examine glucose control during the transition from exenatide twice daily for 30 weeks to exenatide once weekly. Long-term safety and efficacy will be monitored during the open-ended assessment periods. This study will be conducted in approximately 300 subjects with type 2 diabetes treated with diet modification and exercise alone or in combination with a stable regimen of metformin, SU, thiazolidinedione (TZD), a combination of metformin and SU, a combination of metformin and TZD, or a combination of SU and TZD.

Enrollment

303 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
  • Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening.
  • Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
  • (For sub-study) Currently participating in open ended assessment period of main study 2993 LAR105

Exclusion criteria

  • Has been previously exposed to exenatide (Byetta®), exenatide LAR, or any glucagon-like peptide-1 (GLP-1) analog.

  • Received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.

  • Has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:

    • Alpha glucosidase inhibitor or meglitinide within 30 days of screening;
    • Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
    • Regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
    • Regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
    • Regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
    • Prescription or over-the-counter weight loss medications within 6 months of screening.
  • (For sub-study) Subjects will be terminated from study who do not participate in the dual chamber pen substudy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

303 participants in 2 patient groups

Exenatide Once Weekly
Experimental group
Description:
Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
Treatment:
Drug: exenatide, long acting release
Exenatide Twice Daily
Active Comparator group
Description:
subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study. Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device.
Treatment:
Drug: exenatide

Trial contacts and locations

25

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems